Dose-Response Relationship, Drug

"Dose-Response Relationship, Drug" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The relationship between the dose of an administered drug and the response of the organism to the drug.

Descriptor ID	D004305
MeSH Number(s)	G07.690.773.875 G07.690.936.500
Concept/Terms	Dose-Response Relationship, Drug Dose-Response Relationship, Drug Dose-Response Relationships, Drug Drug Dose-Response Relationship Drug Dose-Response Relationships Relationship, Drug Dose-Response Relationships, Drug Dose-Response Dose Response Relationship, Drug

Below are MeSH descriptors whose meaning is more general than "Dose-Response Relationship, Drug".

Biological Sciences [G]
Physiological Phenomena [G07]
Pharmacological and Toxicological Phenomena [G07.690]
Pharmacological Phenomena [G07.690.773]
Dose-Response Relationship, Drug [G07.690.773.875]
Toxicological Phenomena [G07.690.936]
Dose-Response Relationship, Drug [G07.690.936.500]

Below are MeSH descriptors whose meaning is related to "Dose-Response Relationship, Drug".

Below are MeSH descriptors whose meaning is more specific than "Dose-Response Relationship, Drug".

Dose-Response Relationship, Drug
Hormesis
Lethal Dose 50

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Dose-Response Relationship, Drug" by people in this website by year, and whether "Dose-Response Relationship, Drug" was a major or minor topic of these publications.

Bar chart showing 807 publications over 29 distinct years, with a maximum of 66 publications in 2005

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	0	5	5
1996	0	6	6
1997	0	4	4
1998	0	11	11
1999	0	11	11
2000	0	25	25
2001	0	28	28
2002	0	43	43
2003	0	44	44
2004	0	49	49
2005	0	66	66
2006	0	35	35
2007	0	39	39
2008	0	48	48
2009	0	39	39
2010	0	39	39
2011	1	36	37
2012	1	28	29
2013	0	37	37
2014	1	38	39
2015	0	45	45
2016	0	34	34
2017	0	30	30
2018	0	24	24
2019	0	13	13
2020	0	14	14
2021	0	11	11
2022	0	1	1
2024	0	1	1

Below are the most recent publications written about "Dose-Response Relationship, Drug" by people in Profiles.

VanKoten HW, Pence BC, Klinkenberg JR, Das S, Patterson SE. Synthesis and evaluation of anti-Giardia activity of oseltamivir analogs. Bioorg Med Chem Lett. 2025 Feb 01; 116:130035.

View in: PubMed
Elbatrawy AA, Ademoye TA, Alnakhala H, Tripathi A, Plascencia-Villa G, Zhu X, Perry G, Dettmer U, Fortin JS. Exploring the rhodanine universe: Design and synthesis of fluorescent rhodanine-based derivatives as anti-fibrillar and anti-oligomer agents against a-synuclein and 2N4R tau. Bioorg Med Chem. 2024 Dec 15; 116:117990.

View in: PubMed
Bishop JR, Zhou C, Gaedigk A, Krone B, Kittles R, Cook EH, Newcorn JH, Stein MA. Dopamine Transporter and CYP2D6 Gene Relationships with Attention-Deficit/Hyperactivity Disorder Treatment Response in the Methylphenidate and Atomoxetine Crossover Study. J Child Adolesc Psychopharmacol. 2024 Dec; 34(10):458-469.

View in: PubMed
Metibemu DS, Adeyinka OS, Falode J, Hampton T, Crown O, Ojobor JC, Narayanan A, Julander J, Ogungbe IV. Inhibitor of the non-structural protein 2 protease shows promising efficacy in mouse models of chikungunya. Eur J Med Chem. 2024 Nov 15; 278:116808.

View in: PubMed
Ahmed MA, Krishna R, Rayad N, Albusaysi S, Mitra A, Shang E, Hon YY, AbuAsal B, Bakhaidar R, Roman YM, Bhattacharya I, Cloyd J, Patel M, Kartha RV, Younis IR. Getting the Dose Right in Drug Development for Rare Diseases: Barriers and Enablers. Clin Pharmacol Ther. 2024 Dec; 116(6):1412-1432.

View in: PubMed
Liu W, Mousa AAK, Hopkins AM, Wu YF, Thu KL, Campbell M, Lees SJ, Ramachandran R, Hou J. Lysophosphatidic Acid Receptor 1 (LPA1) Antagonists as Potential Migrastatics for Triple Negative Breast Cancer. ChemMedChem. 2024 Aug 19; 19(16):e202400013.

View in: PubMed
Ferraris D, Lapidus R, Truong P, Bollino D, Carter-Cooper B, Lee M, Chang E, LaRossa-Garcia M, Dash S, Gartenhaus R, Choi EY, Kipe O, Lam V, Mason K, Palmer R, Williams E, Ambulos N, Kamangar F, Zhang Y, Kapadia B, Jing Y, Emadi A. Pre-Clinical Activity of Amino-Alcohol Dimeric Naphthoquinones as Potential Therapeutics for Acute Myeloid Leukemia. Anticancer Agents Med Chem. 2022; 22(2):239-253.

View in: PubMed
Gambardella A, Licata G, Calabrese G, De Rosa A, Alfano R, Argenziano G. Dual Efficacy of Upadacitinib in 2 Patients With Concomitant Severe Atopic Dermatitis and Alopecia Areata. Dermatitis. 2021 Oct 01; 32(1S):e85-e86.

View in: PubMed
Cruz B, Ortegon S, Giner P, Matos-Ocasio F, Rodriguez-Crespo A, Uribe KP, Galindo KI, Serafine KM, Nazarian A, O'Dell LE. The emergence of insulin resistance following a chronic high-fat diet regimen coincides with an increase in the reinforcing effects of nicotine in a sex-dependent manner. Neuropharmacology. 2021 12 01; 200:108787.

View in: PubMed
Nayeem N, Yeasmin A, Cobos SN, Younes A, Hubbard K, Contel M. Investigation of the Effects and Mechanisms of Anticancer Action of a Ru(II)-Arene Iminophosphorane Compound in Triple Negative Breast Cancer Cells. ChemMedChem. 2021 11 05; 16(21):3280-3292.

View in: PubMed

People

Explore

Similar Concepts

Top Journals